Abstract: The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild type p53 suppressor by interfering with the interaction between human p53 and human MDM2.

Abstract: The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild type p53 suppressor by interfering with the interaction between human p53 and human MDM2.

Abstract: The present invention concerns a new assay which allows the identification of compounds which inhibit the formation of complexes between a product of the double minute 2 gene (“dm2”) and p53 but not between p53 and DNA. Both the complex formation of labeled DNA, C-terminally truncated p53 and dm2 and disruption of dm2 from the labeled DNA-p53 complex by an inhibitor of the p53-dm2 interaction can be detected by a gel shift assay procedure. This assay permits the selection of compounds which, besides their inhibitory property, do not alter p53 specific DNA binding and do not disturb p53 conformation required for DNA binding or formation of active tetramer.

Abstract: The invention relates to purified proteins induced in human cells by interferon &agr; or &bgr;, RNAs, DNAs and hybrid vectors coding for said proteins, hosts transformed with such a hybrid vector, processes for the preparation and purification of these proteins, DNAs, vectors and hosts, monoclonal antibodies specific to these proteins, monoclonal antibody derivatives, hybridoma cell lines secreting these monoclonal antibodies, the use of the monoclonal antibodies and their derivatives in the qualitative and quantitative determination of these proteins, test kits containing the monoclonal antibodies, and pharmaceutical preparations containing said proteins. A protein of the invention shows antiviral properties ascribed to interferons and may be a valuable indicator of the cell response to an interferon therapy.

Abstract: The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounsa, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild typr p53 suppressor by interfering with the interaction between human p53 and human MDM2.

Abstract: The invention relates to purified proteins induced in human cells by interferon .alpha. or .beta., RNAs, DNAs and hybrid vectors coding for said proteins, hosts tranformed with such a hybrid vector, processes for the preparation and purification of these proteins, DNAs, vectors and hosts, monoclonal antibodies specific to these proteins, monoclonal antibody derivatives, hybridoma celll lines secreting these monoclonal antibodies specific to these proteins, and their derivatives in the qualitative and quantitative determination of these proteins, test kits containing the monoclonal antibodies, and pharmaceutical preparations containing said proteins. A protein of the invention shows antiviral properties ascribed to interferons and may be a valuable indicator of the cell response to an interferon therapy.

Abstract: The invention relates to purified proteins induced in human cells by interferon .alpha. or .beta., RNAs, DNAs and hybrid vectors coding for said proteins, hosts transformed with such a hybrid vector, processes for the preparation and purification of these proteins, DNAs, vectors and hosts, monoclonal antibodies specific to these proteins, monoclonal antibody derivatives, hybridoma cell lines secreting these monoclonal antibodies, the use of the monoclonal antibodies and their derivatives in the qualitative and quantitative determination of these proteins, test kits containing the monoclonal antibodies, and pharmaceutical preparations containing said proteins. A protein of the invention shows antiviral properties ascribed to interferons and may be a valuable indicator of the cell response to an interferon therapy.

Abstract: The invention relates to purified proteins induced in human cells by interferon .alpha. or .beta., RNAs, DNAs and hybrid vectors coding for said proteins, hosts transformed with such a hybrid vector, processes for the preparation and purification of these proteins, DNAs, vectors and hosts, monoclonal antibodies specific to these proteins, monoclonal antibody derivatives, hybridoma cell lines secreting these monoclonal antibodies, the use of the monoclonal antibodies and their derivatives in the qualitative and quantitative determination of these proteins, test kits containing the monoclonal antibodies, and pharmaceutical preparations containing said proteins. A protein of the invention shows antiviral properties ascribed to interferons and may be a valuable indicator of the cell response to an interferon therapy.

Abstract: Described is a synergistic pharmaceutical combination preparation comprising as component A a hybrid .alpha.-interferon the structure of which is derived from human interferon-.alpha.-D and -.alpha.-B gene fragments and as component B a muramylpeptide. The preparation can be used for treating viral diseases or reducing the formation of metastases of certain tumors.